Lipocine (LPCN) Accounts Payables (2011 - 2025)
Lipocine's (LPCN) quarterly Accounts Payables came in at $971822.0 in Q4 2025, up 257.69% YoY from $271696.0 in Q4 2024, and up 12.81% on a QoQ basis from $861452.0 in Q3 2025.
Lipocine (LPCN) Accounts Payables (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Accounts Payables data on file, last reported at $971822.0 in Q4 2025.
- Quarterly Accounts Payables rose 257.69% year-over-year to $971822.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $971822.0 (up 257.69% YoY) and the FY2025 annual result came in at $971822.0, up 257.69% from the prior year.
- Accounts Payables improved to $971822.0 in Q4 2025, from $861452.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.4 million in Q4 2023 to a low of $271696.0 in Q4 2024.
- A 5-year average of $705967.5 and a median of $650950.5 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables plunged 80.54% — and 2025, when it surged 257.69%.
- Tracing LPCN's Accounts Payables over 5 years: stood at $1.3 million in 2021, then slumped by 53.43% to $600388.0 in 2022, then surged by 132.51% to $1.4 million in 2023, then sank by 80.54% to $271696.0 in 2024, then surged by 257.69% to $971822.0 in 2025.
- The last three Accounts Payables figures came in at $971822.0 (Q4 2025), $861452.0 (Q3 2025), and $442994.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | 971,822.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 971,822.00 |
| Sep 30, 2025 | 861,452.00 |
| Jun 30, 2025 | 442,994.00 |
| Mar 31, 2025 | 360,239.00 |
| Dec 31, 2024 | 271,696.00 |
| Sep 30, 2024 | 285,347.00 |
| Jun 30, 2024 | 448,798.00 |
| Mar 31, 2024 | 671,445.00 |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 517,587.00 |
| Mar 31, 2023 | 796,476.00 |
| Dec 31, 2022 | 600,388.00 |
| Sep 30, 2022 | 630,456.00 |
| Jun 30, 2022 | 814,004.00 |
| Mar 31, 2022 | 469,887.00 |
| Dec 31, 2021 | 1.29 Mn |
| Sep 30, 2021 | 725,552.00 |
| Jun 30, 2021 | 906,476.00 |
| Mar 31, 2021 | 558,344.00 |